Galena Biopharma Expands Folate Binding Protein Vaccine Intellectual Property With Notice of Allowance for U.S. Patent

Galena Biopharma, Inc.

today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a Composition of Matter patent covering Folate Binding Peptide peptide variants for use either alone or in combination with the FBP vaccine, E39. Additionally, the patent lays the foundation for additional intellectual property for the use of these variants in a novel vaccination strategy that could be applied to any peptide-based vaccine.